{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:51:10Z","timestamp":1790819470971,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1038\/s41375-023-02071-z","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T12:01:58Z","timestamp":1698494518000},"page":"181-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3223-1893","authenticated-orcid":false,"given":"Christina","family":"Pfeiffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9929-1861","authenticated-orcid":false,"given":"Alexander M.","family":"Grandits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Asnagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-2201","authenticated-orcid":false,"given":"Anja","family":"Schneller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Zojer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-9715","authenticated-orcid":false,"given":"Martin","family":"Schreder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Bolomsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3056-5419","authenticated-orcid":false,"given":"Philip A.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"2071_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/PPO.0000000000000355","volume":"25","author":"R Szalat","year":"2019","unstructured":"Szalat R, Munshi NC. Novel Agents in Multiple Myeloma. Cancer J. 2019;25:45\u201353.","journal-title":"Cancer J"},{"key":"2071_CR2","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1080\/10428194.2021.1957875","volume":"62","author":"S Zanwar","year":"2021","unstructured":"Zanwar S, Kumar S. Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. Leuk Lymphoma. 2021;62:3087\u201397.","journal-title":"Leuk Lymphoma"},{"key":"2071_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133:660\u201375.","journal-title":"Blood"},{"key":"2071_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2015.309","volume":"30","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Heuck CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, et al. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. 2016;30:423\u201330.","journal-title":"Leukemia"},{"key":"2071_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149\u201357.","journal-title":"Leukemia"},{"key":"2071_CR6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443.","journal-title":"Leukemia"},{"key":"2071_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF00873913","volume":"11","author":"M Moore","year":"1993","unstructured":"Moore M, Maroun J, Robert F, Natale R, Neidhart J, Dallaire B, et al. Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer. Invest New Drugs. 1993;11:61\u201365.","journal-title":"Invest New Drugs"},{"key":"2071_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF00685106","volume":"31","author":"S Urba","year":"1992","unstructured":"Urba S, Doroshow J, Cripps C, Robert F, Velez-Garcia E, Dallaire B, et al. Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 1992;31:167\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2071_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/oxfordjournals.annonc.a057680","volume":"1","author":"PF Dodion","year":"1990","unstructured":"Dodion PF, Wagener T, Stoter G, Drozd A, Lev LM, Skovsgaard T, et al. Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC. Ann Oncol Off J Eur Soc Med Oncol. 1990;1:79\u201380.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2071_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40170-021-00250-z","volume":"9","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Tao L, Zhou X, Zuo Z, Gong J, Liu X, et al. DHODH and cancer: promising prospects to be explored. Cancer Metab. 2021;9:22.","journal-title":"Cancer Metab"},{"key":"2071_CR11","doi-asserted-by":"publisher","first-page":"33035","DOI":"10.1074\/jbc.R400007200","volume":"279","author":"DR Evans","year":"2004","unstructured":"Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem. 2004;279:33035\u20138.","journal-title":"J Biol Chem"},{"key":"2071_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0021-9258(20)89934-7","volume":"222","author":"I Lieberman","year":"1956","unstructured":"Lieberman I. Enzymatic amination of uridine triphosphate to cytidine triphosphate. J Biol Chem. 1956;222:765\u201375.","journal-title":"J Biol Chem"},{"key":"2071_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nature13386","volume":"510","author":"E Martin","year":"2014","unstructured":"Martin E, Palmic N, Sanquer S, Lenoir C, Hauck F, Mongellaz C, et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature. 2014;510:288.","journal-title":"Nature"},{"key":"2071_CR14","doi-asserted-by":"crossref","unstructured":"Martin E, Minet N, Boschat A-C, Sanquer S, Sobrino S, Lenoir C, et al. Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation. JCI insight. 2020;5:e133880.","DOI":"10.1172\/jci.insight.133880"},{"key":"2071_CR15","doi-asserted-by":"publisher","first-page":"e2107968118","DOI":"10.1073\/pnas.2107968118","volume":"118","author":"EM Lynch","year":"2021","unstructured":"Lynch EM, DiMattia MA, Albanese S, van Zundert GCP, Hansen JM, Quispe JD, et al. Structural basis for isoform-specific inhibition of human CTPS1. Proc Natl Acad Sci. 2021;118:e2107968118.","journal-title":"Proc Natl Acad Sci"},{"key":"2071_CR16","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1097\/HS9.0000000000000864","volume":"7","author":"H Asnagli","year":"2023","unstructured":"Asnagli H, Minet N, Pfeiffer C, Hoeben E, Lane R, Laughton D, et al. CTP Synthase 1 Is a Novel Therapeutic Target in Lymphoma. HemaSphere. 2023;7:e864.","journal-title":"HemaSphere"},{"key":"2071_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","volume":"86","author":"DG Altman","year":"1994","unstructured":"Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using \u2018optimal\u2019 cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829\u201335.","journal-title":"J Natl Cancer Inst"},{"key":"2071_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a Cancer Dependency Map. Cell. 2017;170:564\u2013576.e16.","journal-title":"Cell"},{"key":"2071_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02540-7","volume":"22","author":"JM Dempster","year":"2021","unstructured":"Dempster JM, Boyle I, Vazquez F, Root DE, Boehm JS, Hahn WC, et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 2021;22:343.","journal-title":"Genome Biol"},{"key":"2071_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/gcc.20668","volume":"48","author":"L Agnelli","year":"2009","unstructured":"Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer. 2009;48:603\u201314.","journal-title":"Genes Chromosomes Cancer"},{"key":"2071_CR21","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","volume":"67","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67:2982\u20139.","journal-title":"Cancer Res"},{"key":"2071_CR22","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543\u201353.","journal-title":"Blood"},{"key":"2071_CR23","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"2071_CR24","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.leu.2404253","volume":"20","author":"I Hanamura","year":"2006","unstructured":"Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J. Prognostic value of Cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia. 2006;20:1288\u201390.","journal-title":"Leukemia"},{"key":"2071_CR25","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177\u201388.","journal-title":"Blood"},{"key":"2071_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00928361","volume":"140","author":"TW Traut","year":"1994","unstructured":"Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem. 1994;140:1\u201322.","journal-title":"Mol Cell Biochem"},{"key":"2071_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano Y, Moschetta M, Manier S, Glavey S, G\u00f6rg\u00fcn GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263:160\u201372.","journal-title":"Immunol Rev"},{"key":"2071_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2018","unstructured":"Pelletier J, Thomas G, Volarevi\u0107 S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18:51\u201363.","journal-title":"Nat Rev Cancer"},{"key":"2071_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23:74\u201388.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2071_CR30","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1038\/s41375-021-01206-4","volume":"35","author":"H Huang","year":"2021","unstructured":"Huang H, Wang Y, Wang W, Wei X, Gale RP, Li J, et al. A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. Leukemia. 2021;35:3212\u201322.","journal-title":"Leukemia"},{"key":"2071_CR31","doi-asserted-by":"publisher","first-page":"e1010101","DOI":"10.1371\/journal.pgen.1010101","volume":"18","author":"A Ajazi","year":"2022","unstructured":"Ajazi A, Choudhary R, Tronci L, Bachi A, Bruhn C. CTP sensing and Mec1ATR-Rad53CHK1\/CHK2 mediate a two-layered response to inhibition of glutamine metabolism. PLoS Genet. 2022;18:e1010101.","journal-title":"PLoS Genet"},{"key":"2071_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1158\/0008-5472.CAN-21-1707","volume":"82","author":"Z Sun","year":"2022","unstructured":"Sun Z, Zhang Z, Wang Q-Q, Liu J-L. Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells. Cancer Res. 2022;82:1013\u201324.","journal-title":"Cancer Res"},{"key":"2071_CR33","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/leu.2011.94","volume":"25","author":"DK Walters","year":"2011","unstructured":"Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, et al. Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia. 2011;25:1344\u201353.","journal-title":"Leukemia"},{"key":"2071_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nm.3562","volume":"20","author":"F Cottini","year":"2014","unstructured":"Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014;20:599\u2013606.","journal-title":"Nat Med"},{"key":"2071_CR35","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","volume":"5","author":"F Cottini","year":"2015","unstructured":"Cottini F, Hideshima T, Suzuki R, Tai Y-T, Bianchini G, Richardson PG, et al. Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov. 2015;5:972\u201387.","journal-title":"Cancer Discov"},{"key":"2071_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fonc.2017.00098","volume":"7","author":"AB Herrero","year":"2017","unstructured":"Herrero AB, Guti\u00e9rrez NC. Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival. Front Oncol. 2017;7:98.","journal-title":"Front Oncol"},{"key":"2071_CR37","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.3324\/haematol.2018.215210","volume":"105","author":"OA Botrugno","year":"2020","unstructured":"Botrugno OA, Bianchessi S, Zambroni D, Frenquelli M, Belloni D, Bongiovanni L, et al. ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies. Haematologica. 2020;105:2440\u20137.","journal-title":"Haematologica"},{"key":"2071_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","volume":"32","author":"SK Shukla","year":"2017","unstructured":"Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, et al. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 2017;32:71\u201387.","journal-title":"Cancer Cell"},{"key":"2071_CR39","doi-asserted-by":"publisher","first-page":"e0264024","DOI":"10.1371\/journal.pone.0264024","volume":"17","author":"F Conte","year":"2022","unstructured":"Conte F, Sibilio P, Grimaldi AM, Salvatore M, Paci P, Incoronato M. In silico recognition of a prognostic signature in basal-like breast cancer patients. PLoS One. 2022;17:e0264024.","journal-title":"PLoS One"},{"key":"2071_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03206-5","volume":"20","author":"Y Lin","year":"2022","unstructured":"Lin Y, Zhang J, Li Y, Guo W, Chen L, Chen M, et al. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1. J Transl Med. 2022;20:17.","journal-title":"J Transl Med"},{"key":"2071_CR41","doi-asserted-by":"crossref","unstructured":"Minet N, Boschat A-C, Lane R, Laughton D, Beer P, Asnagli H, et al. Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation. Life Sci Alliance. 2023;6:e202302066.","DOI":"10.26508\/lsa.202302066"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02071-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02071-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02071-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:03:56Z","timestamp":1704809036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02071-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2071"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02071-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Philip A. Beer, H\u00e9l\u00e8ne Asnagli and Andrew E. Parker are employees of Step Pharma SAS. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}